In atherosclerosis-prone models, PD-1 blockade accelerates disease progression by enhancing T cell activation, monocyte recruitment, foam cell formation, and endothelial dysfunction—key processes in plaque development and destabilization [73,74,75]. Here, RPL17 is linked to atherosclerosis.